Attached files
| file | filename |
|---|---|
| EX-10.5 - EX-10.5 - ARENA PHARMACEUTICALS INC | arna-ex105_173.htm |
| 10-Q - 10-Q - ARENA PHARMACEUTICALS INC | arna-10q_20160930.htm |
| EX-32.1 - EX-32.1 - ARENA PHARMACEUTICALS INC | arna-ex321_9.htm |
| EX-31.2 - EX-31.2 - ARENA PHARMACEUTICALS INC | arna-ex312_7.htm |
| EX-31.1 - EX-31.1 - ARENA PHARMACEUTICALS INC | arna-ex311_10.htm |
| EX-10.4 - EX-10.4 - ARENA PHARMACEUTICALS INC | arna-ex104_174.htm |
| EX-10.3 - EX-10.3 - ARENA PHARMACEUTICALS INC | arna-ex103_755.htm |
| EX-10.1 - EX-10.1 - ARENA PHARMACEUTICALS INC | arna-ex101_177.htm |
Exhibit 10.2
AMENDMENT NO. 2 TO
ARENA PHARMACEUTICALS, INC.
AMENDED AND RESTATED SEVERANCE BENEFIT PLAN
The Arena Pharmaceuticals, Inc., Amended and Restated Severance Benefit Plan, dated May 9, 2016, as amended (the “Plan”), is hereby further amended as of August 15, 2016, by this Amendment No. 2 as follows:
Vincent E. Aurentz is hereby added to Exhibit A of the Plan, with a Severance Period of 18 months.
To record the adoption of this Amendment No. 2, Arena Pharmaceuticals, Inc., has caused its duly authorized officer to execute the same this 15th day of August 2016.
|
Arena Pharmaceuticals, Inc. |
|
|
|
/s/ Amit Munshi |
|
Amit Munshi |
|
President and Chief Executive Officer |